Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Mitotic Pathway Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FOXM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOXM1 Recombinant Protein (Full-Length / DNA-Binding Domain) High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for DNA-binding and PPI assays. |
View FOXM1 Products |
| Gene Delivery | FOXM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View FOXM1 Products |
| Benchmark Ab | Anti-FOXM1 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, IHC, and ChIP assays. |
View FOXM1 Products |
| Validator | FOXM1 siRNA Set Target-specific knockdown verification to eliminate off-target false positives. |
View FOXM1 Products |
| Related Target A | PLK1 Polo-like kinase 1; phosphorylates and activates FOXM1, forming a critical positive feedback loop in mitosis. |
View PLK1 Products |
| Related Target B | CDK4 Cyclin-dependent kinase 4; upstream regulator of the Rb-E2F pathway that drives FOXM1 expression. |
View CDK4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Transcription Factor Targeting | High-purity DNA-Binding Domain (DBD) proteins designed for robust Electrophoretic Mobility Shift Assays (EMSA). |
| Protein-Protein Interaction (PPI) Screening | Truncated domain constructs with flexible tag options (His, GST, Flag) for TR-FRET and AlphaLISA assays. |
| Lack of Controls | Sequence-derived benchmark antibodies and validated positive control reagents included |
| False Positives in Phenotypic Screening | Sequence-verified siRNA knockdown sets for strict target validation in cell-based models |
Live FOXM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FOXM1 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted transcription factor inhibitors and degraders. As first-generation direct inhibitors reach the preclinical-to-clinical transition, the next wave of R&D is targeting the disruption of FOXM1 protein-protein interactions (PPI) and utilizing PROTAC technologies to achieve complete proteasomal degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Carrick Therapeutics, Academic Spin-offs | Breast Cancer, Ovarian Cancer, Glioblastoma | DNA-Binding Inhibition Assay (Need pure DBD protein) |
| PROTACs / Degraders | Arvinas, Yale University spin-offs | Prostate Cancer, Triple-Negative Breast Cancer (TNBC) | Ubiquitination & Degradation Assay (Need full-length FOXM1) |
| Peptide Vaccines / TCR-T | OncoTherapy Science | Solid Tumors, Pediatric Cancers | HLA binding and antigen presentation validation |